This week saw a series of big-ticket funding rounds for biotech companies, with Apollo Therapeutics and Nimbus Therapeutics both pulling in upwards of $200 million, in a positive sign for private ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

However, the company opted to buy Nimbus Therapeutics' acetyl-CoA carboxylase (ACC) programme instead. Gilead will buy Nimbus Therapeutics' liver drug subsidiary Nimbus Apollo in a $1.2 billion deal.

In addition, it is essential to note that Schrödinger is advancing strategic partnerships with companies such as Ajax Therapeutics, Morphic (acquired by Eli Lilly (NYSE: LLY)), Nimbus ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Naik disclosed that she has received grant support from AbbVie; consulting fees from 23andMe, AbbVie, Aristea Therapeutics, Nimbus Therapeutics, Medscape, Sonoma Biotherapeutics, DAVA Oncology ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after 12 years in management at Japan's biggest ...

The campaign’s centerpiece is a black and gray pair of GEL-NIMBUS 10.1s — a model first introduced in 2024 — which features layered mesh and carbon fiber textures. HAVEN’s foray into ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating ...